Fig. 4: Treatment of mice with 4-OI reverses the exacerbated fatty liver disease in Irg1−/− mice.
Mice on WD were treated with 50 mg kg−1 4-OI in 40% cyclodextrin/PBS or vehicle control (40% cyclodextrin/PBS) for 12 weeks. a,b, Itaconate levels in the plasma (a) and liver (b) were quantified at the indicated times (n = 5 mice per group). c, ORO staining of control diet- (top) and WD- (bottom) fed mice. The images are each representative of 20 non-overlapping images from five different mice per group. d, The sum areas of ORO staining were quantified using ImageJ software (*P = 0.015; ****P < 0.0001 for the indicated comparisons; n = 20). e, Quantitation of ORO (average droplet size) was obtained by dividing the sums of droplet area (d) by the number of droplets/image (**P = 0.002; ****P < 0.0001; n = 20). f, Mesenteric fat weight (five mice per group; P = 0.014 for the indicated group, as compared to all other groups). Data are presented as mean ± s.e.m. A two-sided ANOVA with multiple comparisons was used for statistical analyses.
